Trastuzumab (Herceptin): clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Trastuzumab (Herceptin)

• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
  NCT07610720 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
  NCT07797218 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 690 locations
• Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
  NCT07193394 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations

Common questions

How many recruiting trials involve Trastuzumab (Herceptin)?

4 recruiting trials across 9 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.